Clinical Trial Update: Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

A Phase 1 trial of sublingual Anvirzel for non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anvirzel

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chemotherapeutic Agent Toxicity, Lung Cancer | Phase 1 | Status: WITHDRAWN